TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (NCT07502872)
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Who can join: Review the eligibility criteria below.
Location: Rhode Island Hospital — Providence, Rhode Island
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rhode Island Hospital — Providence, Rhode Island
📞 Contact the Study Coordinator
Phone: (401) 863-3000
Email: BrUOG@brown.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B Cell Lymphoma
- Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia — Honolulu, Hawaii
- Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma — Boston, Massachusetts
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients — Morristown, New Jersey
- Copanlisib Plus Venetoclax in R/R DLBCL — Duarte, California
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers — Basking Ridge, New Jersey
- Split-Dose R-CHOP for Older Adults With DLBCL — Madison, Wisconsin
Explore by condition: All Diffuse Large B Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.